Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 15;14(4):872-886.
doi: 10.4251/wjgo.v14.i4.872.

Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway

Affiliations

Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway

Yong-Jie Teng et al. World J Gastrointest Oncol. .

Abstract

Background: The phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin (PI3K/Akt/mTOR) signalling pathway is crucial for cell survival, differentiation, apoptosis and metabolism. Xihuang pills (XHP) are a traditional Chinese preparation with antitumour properties. They inhibit the growth of breast cancer, glioma, and other tumours by regulating the PI3K/Akt/mTOR signalling pathway. However, the effects and mechanisms of action of XHP in hepatocellular carcinoma (HCC) remain unclear. Regulation of the PI3K/Akt/mTOR signalling pathway effectively inhibits the progression of HCC. However, no study has focused on the XHP-associated PI3K/Akt/mTOR signalling pathway. Therefore, we hypothesized that XHP might play a role in inhibiting HCC through the PI3K/Akt/mTOR signalling pathway.

Aim: To confirm the effect of XHP on HCC and the possible mechanisms involved.

Methods: The chemical constituents and active components of XHP were analysed using ultra-performance liquid chromatography-quadrupole time of flight mass spectrometry (UPLC-Q-TOF-MS). Cell-based experiments and in vivo xenograft tumour experiments were utilized to evaluate the effect of XHP on HCC tumorigenesis. First, SMMC-7721 cells were incubated with different concentrations of XHP (0, 0.3125, 0.625, 1.25, and 2.5 mg/mL) for 12 h, 24 h and 48 h. Cell viability was assessed using the CCK-8 assay, followed by an assessment of cell migration using a wound healing assay. Second, the effect of XHP on the apoptosis of SMMC-7721 cells was evaluated. SMMC-7721 cells were stained with fluorescein isothiocyanate and annexin V/propidium iodide. The number of apoptotic cells and cell cycle distribution were measured using flow cytometry. The cleaved protein and mRNA expression levels of caspase-3 and caspase-9 were detected using Western blotting and quantitative reverse-transcription polymerase chain reaction (RT-qPCR), respectively. Third, Western blotting and RT-qPCR were performed to confirm the effects of XHP on the protein and mRNA expression of components of the PI3K/Akt/mTOR signalling pathway. Finally, the effects of XHP on the tumorigenesis of subcutaneous hepatocellular tumours in nude mice were assessed.

Results: The following 12 compounds were identified in XHP using high-resolution mass spectrometry: Valine, 4-gingerol, myrrhone, ricinoleic acid, glycocholic acid, curzerenone, 11-keto-β-boswellic acid, oleic acid, germacrone, 3-acetyl-9,11-dehydro-β-boswellic acid, 5β-androstane-3,17-dione, and 3-acetyl-11-keto-β-boswellic acid. The cell viability assay results showed that treatment with 0.625 mg/mL XHP extract decreased HCC cell viability after 12 h, and the effects were dose- and time-dependent. The results of the cell scratch assay showed that the migration of HCC cells was significantly inhibited in a time-dependent manner by the administration of XHP extract (0.625 mg/mL). Moreover, XHP significantly inhibited cell migration and resulted in cell cycle arrest and apoptosis. Furthermore, XHP downregulated the PI3K/Akt/mTOR signalling pathway, which activated apoptosis executioner proteins (e.g., caspase-9 and caspase-3). The inhibitory effects of XHP on HCC cell growth were determined in vivo by analysing the tumour xenograft volumes and weights.

Conclusion: XHP inhibited HCC cell growth and migration by stimulating apoptosis via the downregulation of the PI3K/Akt/mTOR signalling pathway, followed by the activation of caspase-9 and caspase-3. Our findings clarified that the antitumour effects of XHP on HCC cells are mediated by the PI3K/Akt/mTOR signalling pathway, revealing that XHP may be a potential complementary therapy for HCC.

Keywords: Antitumour; Apoptosis; Hepatocellular carcinoma; Phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway; Xihuang pills.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Components of Xihuang Pills. The fingerprint of the Xihuang pill was determined using high-resolution mass spectrometry. A: The 12 compounds were labelled according to chromatographic retention times, and their molecular structures were analysed; B: The chemical formulae of 12 compounds. The chemical structures of 12 compounds and chemical formulae obtained from chemsrc (https://m.chemsrc.com/mip/), according to the compound numbering scheme in Table 1.
Figure 2
Figure 2
Xihuang pills extract inhibits the growth and migration of SMMC7721 cells. Cells were treated with different concentrations of the Xihuang pills (XHP) extract (0, 0.3125, 0.625, 1.25, and 2.5 mg/mL) for 12 h, 24 h, and 48 h. Cell viability was measured using Cell Counting Kit-8. A: A representative graph showing the effects of treatment with various concentrations of the XHP extract for 12 h; B: A representative graph showing that treatment with 0.625 mg/mL XHP extract induces a decrease in cell viability after 12 h; C: The migration of SMMC-7721 cells was measured using a cell scratch assay with or without the administration of 0.625 mg/mL XHP for 48 h. Data are presented as the means ± SD. aP < 0.05 and bP < 0.01 compared with the control group.
Figure 3
Figure 3
SMMC-7721 cell apoptosis is induced by Xihuang pills extract. SMMC-7721 cells were stained with annexin V/propidium iodide and fluorescein isothiocyanate after treatment with or without 0.625 mg/mL Xihuang pills (XHP) extract for 12 h. A and B: Flow cytometry was used to detect the number of apoptotic cells (A) and the cell cycle distribution (B); C: Cleaved caspase-3 and cleaved caspase-9 protein expression levels were detected by Western blotting, and caspase-3 and caspase-9 mRNA expression levels were detected by reverse-transcription polymerase chain reaction (RT–qPCR); D: After treating SMMC-7721 cells with different concentrations of the XHP extract, cleaved caspase-3 and cleaved caspase-9 protein expression levels were determined using Western blotting, whereas caspase-3 and caspase-9 mRNA expression levels were determined using RT–qPCR. The experiment was repeated three times, and the data are presented as the means ± SD. aP < 0.05 and bP < 0.01 compared with the control group; cP < 0.05 and dP < 0.01 compared with the XHP 0.625 group; eP < 0.05 and fP < 0.01 compared with the XHP 1.25 group.
Figure 4
Figure 4
Inhibitory effects of Xihuang pills extract on the expression of components of the phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin signalling pathway both in vivo and in vitro. A: The protein expression levels and ratios of phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin (PI3K/Akt/mTOR) and p-PI3K/p-Akt/p-mTOR in SMMC-7721 cells were detected using Western blotting; B: PI3K/Akt/mTOR mRNA expression levels in SMMC-7721 cells, as determined using reverse-transcription polymerase chain reaction (RT-qPCR); C: PI3K/Akt/mTOR mRNA expression levels in SMMC-7721 cells after treatment with different concentrations of Xihuang pills (XHP), as measured using RT–qPCR; D: Levels of the PI3K/Akt/mTOR and p-PI3K/p-Akt/p-mTOR proteins in SMMC-7721 cells treated with different concentrations of the XHP extract were detected using Western blotting. Relative protein and mRNA expression levels are shown in representative histograms. The experiment was repeated three times, and the data are presented as the means ± SD. aP < 0.05 and bP < 0.01 compared with the control group; cP < 0.05 and dP < 0.01 compared with the XHP 0.625 group; eP < 0.05 and fP < 0.01 compared with the XHP 1.25 group.
Figure 5
Figure 5
Xihuang pills treatment inhibits tumour growth in vivo. SMMC7721 cells were injected subcutaneously into the lower right side of 5-week-old BALB/c male nude mice. After a model of subcutaneous xenograft tumours was successfully established in nude mice, animals were randomly divided into two groups. Each group was then treated with either 0.2 mL of distilled water (control) or 78 mg/kg of body weight Xihuang pills. A: Representative images of subcutaneous xenograft tumours at the end of treatment; B: Subcutaneous tumour weights measured at the end of the treatment; C: Average subcutaneous tumour volume measured every 2 d; D: Average mouse body weight measured every 2 d. The experiment was repeated three times, and the data are presented as the means ± SD. The results were analysed using one-way analysis of variance, followed by the least significant difference test. aP < 0.05 and bP < 0.01 compared with the control group. XHP: Xihuang pills.

Similar articles

Cited by

References

    1. Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, Baade PD. Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. Front Oncol. 2020;10:171. - PMC - PubMed
    1. Ko KL, Mak LY, Cheung KS, Yuen MF. Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Res. 2020;9 - PMC - PubMed
    1. Rahmani F, Ziaeemehr A, Shahidsales S, Gharib M, Khazaei M, Ferns GA, Ryzhikov M, Avan A, Hassanian SM. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma. J Cell Physiol. 2020;235:4146–4152. - PubMed
    1. Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol. 2011;7:1149–1167. - PubMed
    1. Brotelle T, Bay JO. PI3K-AKT-mTOR pathway: Description, therapeutic development, resistance, predictive/prognostic biomarkers and therapeutic applications for cancer. Bull Cancer. 2016;103:18–29. - PubMed